Providing Phase lll-ready radiolabelled antibody due diligence


A well-capitalized strategic investor looking to enter the radiopharmaceuticals market wanted to conduct clinical due diligence on a novel radioisotope-conjugated antibody designed to treat solid tumors.


We assessed the clinical performance of the product, putting it into the context of cancer therapies in general and benchmarked it against other competing therapies designed to treat the same cancer. We considered whether the product was sufficiently differentiated from its peers, in addition to its likely commercial potential.

We concluded that the clinical trials conducted to date were largely academic and had been performed in a broad range of patient groups. There was little clinical experience in the target patient population of the intended Phase III and in our view an investment in a Phase III program was not justified.

Share on FacebookShare on Google+Tweet about this on TwitterShare on LinkedIn

Stay in touch